Investigational Drug Information for Tenalisib
✉ Email this page to a colleague
What is the drug development status for Tenalisib?
Tenalisib is an investigational drug.
There have been 8 clinical trials for Tenalisib.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 25th 2018.
The most common disease conditions in clinical trials are Lymphoma, Breast Neoplasms, and Lymphoma, T-Cell. The leading clinical trial sponsors are Rhizen Pharmaceuticals SA, Incozen Therapeutics Pvt Ltd, and [disabled in preview].
There are one hundred and eighty-eight US patents protecting this investigational drug and eight hundred and six international patents.
Summary for Tenalisib
| US Patents | 188 |
| International Patents | 806 |
| US Patent Applications | 420 |
| WIPO Patent Applications | 184 |
| Japanese Patent Applications | 19 |
| Clinical Trial Progress | Phase 2 (2018-11-25) |
| Vendors | 44 |
Recent Clinical Trials for Tenalisib
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | Incozen Therapeutics Pvt Ltd | Phase 2 |
| Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) | Rhizen Pharmaceuticals SA | Phase 2 |
| Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | Rhizen Pharmaceuticals SA | Phase 2 |
Clinical Trial Summary for Tenalisib
Top disease conditions for Tenalisib
Top clinical trial sponsors for Tenalisib
US Patents for Tenalisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tenalisib | ⤷ Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Start Trial |
| Tenalisib | ⤷ Start Trial | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Start Trial |
| Tenalisib | ⤷ Start Trial | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | Immunomedics, Inc. (Morris Plains, NJ) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tenalisib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tenalisib | Australia | AU2017261372 | 2036-05-05 | ⤷ Start Trial |
| Tenalisib | Canada | CA3023278 | 2036-05-05 | ⤷ Start Trial |
| Tenalisib | China | CN107847398 | 2036-05-05 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
